Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Sunitinib drug tolerance cell line for renal carcinoma, construction method and application of sunitinib drug tolerance cell line

A kidney cancer sunitinib and drug-resistant cell technology, applied in the field of bioengineering, to achieve the effects of increased tolerance, enhanced invasion and cloning ability, and prolonged proliferation cycle

Active Publication Date: 2019-12-20
SHANGHAI TONGJI HOSPITAL +1
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is no relevant report about the sunitinib-resistant cell line, construction method and application of this patent for renal cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sunitinib drug tolerance cell line for renal carcinoma, construction method and application of sunitinib drug tolerance cell line
  • Sunitinib drug tolerance cell line for renal carcinoma, construction method and application of sunitinib drug tolerance cell line
  • Sunitinib drug tolerance cell line for renal carcinoma, construction method and application of sunitinib drug tolerance cell line

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] Example 1 Establishment and Testing of Renal Cancer Sunitinib-resistant Cell Lines

[0046] 1. Induction of sunitinib-resistant cell lines in renal cell carcinoma

[0047] Drug-resistant cell lines were induced by stepwise increasing drug concentration. The 786-O cells in the logarithmic growth phase were inoculated in RPMI-1640 culture medium containing 10% fetal bovine serum, placed at 37°C, 5% CO 2 cultured in a saturated humidity incubator. Inoculate 786-O cells in a six-well plate. When the cells are fused to 50-60%, add an appropriate amount of Sun to the culture medium for induction. The initial concentration is 2 μM / L. After 24 hours of induction, the drug is withdrawn, and the cells are passaged normally. When returning to normal growth, induce 24h again until the cells can grow normally and be passaged at a concentration of 2 μM / L. Firstly, the concentration of 1 μM / L was increased to induce the cells to grow and pass normally under 6 μM / L Sun, and then the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of biotechnology, in particular to a sunitinib drug tolerance cell line for renal carcinoma, a construction method and an application of the sunitinib drug tolerancecell line. The method comprises the following steps of taking 786-O cells at a logarithmic phase, performing inoculating in an RPMI-1640 culture solution containing 10% fetal calf serum, adopting anin vitro drug concentration step-by-step increasing method, wherein six months are adopted, and finally, obtaining a 786-O-Su cell line which can realize stable growth and culture transfer in a culture system containing 20[mu]M / L. The obtained sunitinib drug tolerance cell line for renal carcinoma can well simulate clinical drug tolerance, and an important platform is provided for research of a renal carcinoma target drug tolerance mechanism, reverse of cell drug tolerance of renal carcinoma, and development and evaluation of a new tumor resisting drug. The construction method is simple to operate, and low in cost, and can provide reference for construction of other drug tolerance cell lines.

Description

technical field [0001] The invention relates to the technical field of bioengineering, in particular to a sunitinib drug-resistant cell line of renal cancer, its construction method and its application. Background technique [0002] Renal Cell Carcinoma (RCC), referred to as kidney cancer, is a common malignant tumor of the urinary system. Clear cell renal cell carcinoma (ccRCC) is the most common and most aggressive histological type of renal cancer, accounting for about 80-85%. The onset of renal cell carcinoma is insidious, nearly one-third of patients have metastasized at the time of first diagnosis, and 20-40% of patients with localized renal cell carcinoma will still develop metastasis after tumor resection, while metastatic renal cell carcinoma (mRCC) ) patients have a very poor prognosis, with a five-year survival rate of no more than 10%. mRCC is not sensitive to traditional chemotherapy and radiotherapy, and targeted therapy is currently the main clinical treatme...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/09C12Q1/02C12R1/91
CPCC12N5/0693G01N33/5011G01N2500/10
Inventor 吕琦王刚敏马春辉王培军张沂南马小龙刘君田举毛新青唐俊军倪玉华
Owner SHANGHAI TONGJI HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com